| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424229100 | Herpetoviridae (e.g., herpesvirus, Mareks disease virus, laryngotracheitis virus, infectious bovine rhinotracheitis virus (IBR), infectious pustular vulvovaginitis virus, bovine herpes virus type 1, Aujeszkys disease virus, feline rhinotracheitis virus, feline herpes virus, etc.) | 20 |
| 20080226677 | Recombinant virus vector for gene transfer into lymphoid cells - A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising the vector, and a nucleic acid cassette comprising a fragment, which is capable of homologous recombination with a herpesvirus genome, and a BAC vector sequence, are provided. | 09-18-2008 |
| 20080241187 | STABILIZATION OF VIRAL COMPOSITIONS - This invention concerns stabilized virus compositions, preferably a herpesvirus which may be an attenuated or genetically modified herpes simplex virus or varicella zoster virus, and a method of stabilizing viruses and immunizing preparations by the addition of sugars, preferably glucose and amino acids, preferably lysine. | 10-02-2008 |
| 20090060951 | DNA VACCINE FOR KOI HERPES VIRUS (KHV) DISEASE - The present invention provides a DNA vaccine for carps for inducing protective immunity against Koi herpesvirus (KHV). The DNA vaccine comprises a DNA comprising a nucleotide sequence encoding an immunogenic polypeptide against Koi herpesvirus (KHV) of carps, or an expression vector comprising the DNA as an active ingredient. | 03-05-2009 |
| 20090246226 | Avian vaccines possessing a positive marker gene - The present invention provides a poultry vaccine containing a positive marker gene. More specifically, recombinant turkey herpesvirus modified by the presence of an extraneous antigen gene that may be used as a positive marker to identify and track vaccinated animals is provided. When inoculated into host animals, a poultry vaccine comprising the recombinant turkey herpesvirus provided in the present invention can elicit serological immune responses to the marker gene product that may be detected by serological assays such as enzyme-linked immunosorbent assay and serum agglutination test, thus enabling easy identification and tracking of vaccinated animals. | 10-01-2009 |
| 20090252763 | BIOLOGICAL ADJUVANTS - A method of enhancing uptake of DNA by a host cell line comprises introducing the DNA into the host cell and contacting the host cell with non-infectious viral particles. The non-infectious particles may be L-particle or PREPS (pre-viral DNA replication envelope particles), for example, those derived from alpha herpesvirus. | 10-08-2009 |
| 20100119550 | RECOMBINANT MULTIVALENT VACCINE - The problems to be solved by the present invention are to provide: a recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing a recombinant varicella-zoster virus; a vector containing a BAC vector sequence in the specific gene of a genomic gene of varicella-zoster virus; cells containing such a vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; a nucleic acid cassette containing the BAC vector sequence; and a multivalent vaccine. The above problems were solved by developing a process for producing a recombinant varicella-zoster virus, wherein the BAC vector sequence is inserted into a specific virus gene. | 05-13-2010 |
| 20100226940 | HERPES SIMPLEX VIRUS MUTANT ICP0 - A mutant herpesvirus that has a mutated gene that encodes a mutant infected cell protein 0 (ICP0) can be used in therapeutic methods as well as in diagnostics and research experiments. The encoded mutant ICP0 protein can be altered in one or more regions of ICP0 that are substantially conserved between two or more herpesviruses and/or within a phosphorylation region. The mutant herpesvirus can be substantially avirulent and immunogenic. | 09-09-2010 |
| 20100330122 | VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND ANTIGENS - The present invention discloses novel Varicella Zoster Virus (VZV) virus-like particles (VLPs) comprising glycoprotein E of VZV. The invention also discloses vaccine formulations of the VZV-VLPs and methods of inducing an immune response in subjects. | 12-30-2010 |
| 20120076823 | Vector - The present invention relates to a herpes virus vector which comprises a modified genomic sequence encoding a microRNA (miRNA) against a target sequence. The herpes virus vector may be used as or in a vaccine to prevent and/or treat a disease. | 03-29-2012 |
| 20120269854 | Method of Enhancing KSHV LANA1 Immunogenicity - An immunogenically-enhanced Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (“KSHV LANA1”) polypeptide and related methods of eliciting an immune response to KSHV LANA1 are provided. Also described herein is a novel polypeptide capable of inhibiting degradation of a protein or retarding synthesis of a protein when attached to or incorporated within that protein. | 10-25-2012 |
| 20130195918 | Equine Herpesvirus 1 Vaccine and Vector and Uses Thereof - We have constructed a mutant EHV-1 that is lacking the entire 12.7 kbp IR segment of the viral genome and found the mutant EHV-1 to be replication competent, to have the ability to replicate in mammalian cell types (including human cells), and to exhibit reduced virulence in the mouse model of EHV-1 virulence. | 08-01-2013 |
| 20130202638 | VACCINE AGAINST BETA-HERPESVIRUS INFECTION AND USE THEREOF - The present invention is related to a beta-herpesvirus, wherein the beta-herpesvirus is spread-deficient. | 08-08-2013 |
| 20140030292 | ANTIGEN DELIVERY PLATFORMS - This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development. | 01-30-2014 |
| 20140255447 | PRODUCTION OF AVIAN EMBRYO CELLS - The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as MDV. The invention also relates to methods for the preparation of vaccines using such cells or viruses. | 09-11-2014 |
| 20140348875 | KOI HERPESVIRUS VACCINE - The present invention relates to a recombinant Koi herpesvirus (KHV), methods for the production of such KHV, cells comprising such KHV and the use of such KHV as vector and in vaccines for the prevention and/or therapeutic treatment of a disease in fish caused by Koi herpesvirus in carp such as | 11-27-2014 |
| 20150376569 | PRODUCTION OF AVIAN EMBRYO CELLS - The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as MDV. The invention also relates to methods for the preparation of vaccines using such cells or viruses. | 12-31-2015 |
| 20160017284 | CYPRINID HERPESVIRUS II-SENSITIVE BRAIN TISSUE CELL LINE OF CARASSIUS AURATUS GIBELIO AND ESTABLISHING METHOD AND USE THEREOF - The present invention discloses a cyprinid herpesvirus II-sensitive brain tissue cell line of | 01-21-2016 |
| 20160051663 | METHODS AND DEVICES FOR CANINE HERPESVIRUS 1 (CHV-1) DETECTION AND PREVENTION - Methods for detection of canine herpes virus 1 (CHV-1) in archived paraffin-embedded tissue are provided. The methods use CHV-1 glycoprotein B (gB)-specific PCR to detect the CHV-1. A vaginal sleeve that protects puppies from contracting CHV-1 by contact with the mother's vaginal wall during birth is also provided. The sleeve is inserted into the vagina of a pregnant female dog prior to birth and puppies traverse the birth canal through the sleeve without coming into direct contact with vaginal tissue. Compositions and methods of immunizing against CHV-1 in dogs of all ages are also provided. | 02-25-2016 |
| 20160152956 | METHOD FOR SELECTING A PERMISSIVE CELL LINE FOR REPLICATING AVIAN VIRUSES | 06-02-2016 |
| 20190144507 | ANTIGEN DELIVERY PLATFORMS | 05-16-2019 |
| 20080226677 | Recombinant virus vector for gene transfer into lymphoid cells - A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising the vector, and a nucleic acid cassette comprising a fragment, which is capable of homologous recombination with a herpesvirus genome, and a BAC vector sequence, are provided. | 09-18-2008 |
| 20080241187 | STABILIZATION OF VIRAL COMPOSITIONS - This invention concerns stabilized virus compositions, preferably a herpesvirus which may be an attenuated or genetically modified herpes simplex virus or varicella zoster virus, and a method of stabilizing viruses and immunizing preparations by the addition of sugars, preferably glucose and amino acids, preferably lysine. | 10-02-2008 |
| 20090060951 | DNA VACCINE FOR KOI HERPES VIRUS (KHV) DISEASE - The present invention provides a DNA vaccine for carps for inducing protective immunity against Koi herpesvirus (KHV). The DNA vaccine comprises a DNA comprising a nucleotide sequence encoding an immunogenic polypeptide against Koi herpesvirus (KHV) of carps, or an expression vector comprising the DNA as an active ingredient. | 03-05-2009 |
| 20090246226 | Avian vaccines possessing a positive marker gene - The present invention provides a poultry vaccine containing a positive marker gene. More specifically, recombinant turkey herpesvirus modified by the presence of an extraneous antigen gene that may be used as a positive marker to identify and track vaccinated animals is provided. When inoculated into host animals, a poultry vaccine comprising the recombinant turkey herpesvirus provided in the present invention can elicit serological immune responses to the marker gene product that may be detected by serological assays such as enzyme-linked immunosorbent assay and serum agglutination test, thus enabling easy identification and tracking of vaccinated animals. | 10-01-2009 |
| 20090252763 | BIOLOGICAL ADJUVANTS - A method of enhancing uptake of DNA by a host cell line comprises introducing the DNA into the host cell and contacting the host cell with non-infectious viral particles. The non-infectious particles may be L-particle or PREPS (pre-viral DNA replication envelope particles), for example, those derived from alpha herpesvirus. | 10-08-2009 |
| 20100119550 | RECOMBINANT MULTIVALENT VACCINE - The problems to be solved by the present invention are to provide: a recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing a recombinant varicella-zoster virus; a vector containing a BAC vector sequence in the specific gene of a genomic gene of varicella-zoster virus; cells containing such a vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; a nucleic acid cassette containing the BAC vector sequence; and a multivalent vaccine. The above problems were solved by developing a process for producing a recombinant varicella-zoster virus, wherein the BAC vector sequence is inserted into a specific virus gene. | 05-13-2010 |
| 20100226940 | HERPES SIMPLEX VIRUS MUTANT ICP0 - A mutant herpesvirus that has a mutated gene that encodes a mutant infected cell protein 0 (ICP0) can be used in therapeutic methods as well as in diagnostics and research experiments. The encoded mutant ICP0 protein can be altered in one or more regions of ICP0 that are substantially conserved between two or more herpesviruses and/or within a phosphorylation region. The mutant herpesvirus can be substantially avirulent and immunogenic. | 09-09-2010 |
| 20100330122 | VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND ANTIGENS - The present invention discloses novel Varicella Zoster Virus (VZV) virus-like particles (VLPs) comprising glycoprotein E of VZV. The invention also discloses vaccine formulations of the VZV-VLPs and methods of inducing an immune response in subjects. | 12-30-2010 |
| 20120076823 | Vector - The present invention relates to a herpes virus vector which comprises a modified genomic sequence encoding a microRNA (miRNA) against a target sequence. The herpes virus vector may be used as or in a vaccine to prevent and/or treat a disease. | 03-29-2012 |
| 20120269854 | Method of Enhancing KSHV LANA1 Immunogenicity - An immunogenically-enhanced Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (“KSHV LANA1”) polypeptide and related methods of eliciting an immune response to KSHV LANA1 are provided. Also described herein is a novel polypeptide capable of inhibiting degradation of a protein or retarding synthesis of a protein when attached to or incorporated within that protein. | 10-25-2012 |
| 20130195918 | Equine Herpesvirus 1 Vaccine and Vector and Uses Thereof - We have constructed a mutant EHV-1 that is lacking the entire 12.7 kbp IR segment of the viral genome and found the mutant EHV-1 to be replication competent, to have the ability to replicate in mammalian cell types (including human cells), and to exhibit reduced virulence in the mouse model of EHV-1 virulence. | 08-01-2013 |
| 20130202638 | VACCINE AGAINST BETA-HERPESVIRUS INFECTION AND USE THEREOF - The present invention is related to a beta-herpesvirus, wherein the beta-herpesvirus is spread-deficient. | 08-08-2013 |
| 20140030292 | ANTIGEN DELIVERY PLATFORMS - This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development. | 01-30-2014 |
| 20140255447 | PRODUCTION OF AVIAN EMBRYO CELLS - The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as MDV. The invention also relates to methods for the preparation of vaccines using such cells or viruses. | 09-11-2014 |
| 20140348875 | KOI HERPESVIRUS VACCINE - The present invention relates to a recombinant Koi herpesvirus (KHV), methods for the production of such KHV, cells comprising such KHV and the use of such KHV as vector and in vaccines for the prevention and/or therapeutic treatment of a disease in fish caused by Koi herpesvirus in carp such as | 11-27-2014 |
| 20150376569 | PRODUCTION OF AVIAN EMBRYO CELLS - The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as MDV. The invention also relates to methods for the preparation of vaccines using such cells or viruses. | 12-31-2015 |
| 20160017284 | CYPRINID HERPESVIRUS II-SENSITIVE BRAIN TISSUE CELL LINE OF CARASSIUS AURATUS GIBELIO AND ESTABLISHING METHOD AND USE THEREOF - The present invention discloses a cyprinid herpesvirus II-sensitive brain tissue cell line of | 01-21-2016 |
| 20160051663 | METHODS AND DEVICES FOR CANINE HERPESVIRUS 1 (CHV-1) DETECTION AND PREVENTION - Methods for detection of canine herpes virus 1 (CHV-1) in archived paraffin-embedded tissue are provided. The methods use CHV-1 glycoprotein B (gB)-specific PCR to detect the CHV-1. A vaginal sleeve that protects puppies from contracting CHV-1 by contact with the mother's vaginal wall during birth is also provided. The sleeve is inserted into the vagina of a pregnant female dog prior to birth and puppies traverse the birth canal through the sleeve without coming into direct contact with vaginal tissue. Compositions and methods of immunizing against CHV-1 in dogs of all ages are also provided. | 02-25-2016 |
| 20160152956 | METHOD FOR SELECTING A PERMISSIVE CELL LINE FOR REPLICATING AVIAN VIRUSES | 06-02-2016 |
| 20190144507 | ANTIGEN DELIVERY PLATFORMS | 05-16-2019 |
